A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2481 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-24

Study Completion Date

2021-12-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

AURIGA is designed to collect data from routine clinical practice on the effectiveness and utilization of intravitreal aflibercept in the treatment of visual impairment due to diabetic macular edema (DME) or macula edema secondary to retinal vein occlusion (RVO).

The primary objective of this observational study (OS) is to evaluate the effectiveness of intravitreal aflibercept in 4 cohorts (with/without prior treatment in DME or macular edema secondary to RVO) in each of the participating countries.

Additionally, utilization and treatment regimens in routine clinical practice will be described.

Health care resources and services as well as health out-comes related to vision loss will be evaluated based on information collected using the AURIGA patient questionnaires.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravitreal Aflibercept Injection in Vision Impairment Due to DME

NCT01331681

Diabetes Mellitus Macular Edema

COMPLETED PHASE3

DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact

NCT00789477

Diabetic Macular Edema

COMPLETED PHASE2

Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement

NCT01783886

Macular Edema

COMPLETED PHASE3

A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema

NCT02850263

Macular Edema

COMPLETED

A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema

NCT05511038

Diabetic Macular Edema

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Macular Edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

* For DME

\-- Female and male patients of legal age, as defined by local regulations and local product labels, with visual impairment due to DME
* For macular edema secondary to RVO

\-- Female and male patients of legal age, as defined by local regulations and local product labels, with visual impairment due to macular edema secondary to RVO
* Patient for whom the decision to initiate treatment with aflibercept is made prior to and independent from study participation
* Signed informed consent.

Exclusion Criteria

* Any contraindications as listed in the local intravitreal aflibercept SmPC (summary of product characteristics)
* Current participation in any other clinical (interventional) study or in any other anti-VEGF study
* Receipt of systemic anti-VEGF and pro-VEGF treatment
* Structural damage to the center of the macula in either eye that is likely to preclude improvement in VA following the resolution of macular edema or any other condition expected to permanently limit VA outcomes over the course of the study
* Patients with prior retinal surgery
* Any prior treatment with aflibercept
* History of stroke or transient ischemic attacks within the last 6 months
* Laser photocoagulation (panretinal or macular) in the study eye within 90 days of Day 1
* For patients with prior treatment (i.e. patients that previously have been treated with intravitreal anti-VEGF or steroids):

* Previous treatment of the study eye with anti-angiogenic drugs or laser within the last 3 months and patients with ocular surgery of the study eye within the last 3 months
* Intravitreal dexamethasone or triamcinolone in the study eye within the last 3 months
* Fluocinolone implant within the last 3 years
* Dexamethasone implant within the last 6 months
* For DME

\-- Concomitant therapy with any other agent to treat DME in the study eye.
* For macular edema secondary to RVO

* Patients who have received or who require pan retinal photocoagulation due to neovascularization
* Concomitant therapy with any other agent to treat macular edema secondary to RVO in the study eye.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No